Abstract The 2022 World Health Organization (WHO) classification of the urinary and male
genital tumors was recently published by the International Agency for Research on Cancer …

Simple Summary In this review, we examined relevant clinical trial results with immune
checkpoint inhibitors in patients with metastatic urothelial cancer. We also focused on the …

Immunotherapy with checkpoint inhibitors is well established as an effective treatment for
non-small cell lung cancer and melanoma. The list of approved indications for treatment with …

Abstract Five programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors
are currently approved for treatment of locally advanced or metastatic urothelial carcinoma …

Objectives To evaluate variant histologies (VHs) for disease‐specific survival (DSS) in
patients with invasive urothelial bladder cancer (BCa) undergoing radical cystectomy (RC) …

The current personalized oncology era has witnessed significant efforts to integrate clinical,
pathological, and molecular classifications. The growing need for molecular biomarkers to …

Abstract The Genitourinary Pathology Society (GUPS) undertook a critical review of the
recent advances in bladder cancer focusing on important topics of high interest for the …

Objective Immunotherapy is an attractive treatment for breast cancer. Cancer-testis antigens
(CTAs) are potential targets for immunotherapy for their restricted expression. Here, we …

Histologically, bladder cancer is a heterogeneous group comprising urothelial carcinoma
(UC), squamous cell carcinoma, adenocarcinomas (ACs), urachal carcinomas (UrCs), and …

Background PD-L1 immunohistochemical expression is used as an important theranostic
marker in various malignancies, including head and neck squamous cell carcinoma …